Tag - ARWR

Developments

Arrowhead reports positive interim results from Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) reported positive 24-week data from its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. ARO-ATT is a subcutaneously...

September 16, 2020

Developments

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...

December 20, 2019

Developments

Arrowhead Pharma’s RNAi candidate gets FDA clearance for Phase 2/3 trial

Arrowhead Pharma (NASDAQ:ARWR) received FDA clearance to proceed with its adaptive Phase 2/3 trial evaluating ARO-AAT in patients with alpha-1 antitrypsin (AAT) deficiency-associated liver disease. AAT deficiency is a...

April 15, 2019

Tag - ARWR

Arrowhead reports positive interim results from Phase 2 alpha-1 liver disease trial

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Arrowhead Pharma’s RNAi candidate gets FDA clearance for Phase 2/3 trial

General

More